Additional screening for mutations in other JAK2 exons from PV patients negative for the JAK2V617F mutation revealed four novel mutations in exon 12.9, 10 The ...

The JAK2 V617F mutation is a result of a single change in the DNA nucleotide base pair that causes a substitution of a valine amino acid for a phenylalanine ...

JAK2 V617F mutation is acquired as opposed to inherited and results in the change of a single DNA nucleotide base pair. In JAK2, this kind of ...

The JAK2V617F tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. Int J ...

The JAK2 V617F is present in 95% to 98% of polycythemia vera, 50% to 60% of primary myelofibrosis (PMF), and 50% to 60% of essential thrombocythemia (ET).

It has been demonstrated that the JAK2 V617F point mutation, a common molecular genetic abnormality, occurs in polycythemia vera (PV), essential thrombocythemia histiocytosis (ET) and primary myelofibrosis (PMF); therefore, the JAK2 mutation may be an important diagnostic tool for the detection of myeloproliferative ...

Background: The Janus kinase-2 (JAK-2) V617F mutation has been recently reported in patients with myeloproliferative disorders (MPD), which is believed to ...

The JAK2 V617F mutation in MPDs can be detected by a variety of methods. The simplest method is to isolate DNA from whole blood leukocytes and use PCR-direct sequencing. However, since the mutation is acquired and restricted to the myeloid lineage this method has a sensitivity of between 20 to 30%.